Trending peptide

Epitalon

Also called Epithalon, Epitalone, AEDG peptide, Ala-Glu-Asp-Gly, Tetrapeptide AEDG, AE-0 peptide.

Epitalon is a tiny lab-made chain of four amino acids (building blocks of proteins), copied from the make-up of an extract from cow pineal glands. It is not an approved medicine in the US, and we found no approval by any other regulator. Most of the research comes from one Russian group, in cells and animals, with a few small human studies. It has never been tested for safety in a proper trial.

Epitalon is not an approved medicine for these uses in most countries. This page explains the science and the law; it does not give dosing, sourcing or usage advice.

How strong is the evidence?

AnecdoteAnimalsHuman trialsApproved
Small human. Small or uncontrolled studies in people.The evidence is small, mostly from a single research network, and largely not from modern controlled trials. Human: (1) a 2002 report from the originating group that injection beside the eye produced a positive clinical effect in 90% of cases in patients with degenerative retinal lesions (the abstract gives no patient numbers or comparison; a 2025 review's account describes 162 patients and a comparison group on conventional treatment, but no placebo and no between-group results); (2) a small randomised placebo-controlled sublingual study in women aged 40-50 working night shifts (Ivko 2021, 75 women, 40 with low urinary melatonin metabolite split into treatment and placebo groups for 20 days) in which the treated group's metabolite level rose 1.7-fold; sleep outcomes were not assessed and no safety data were reported; FDA noted blinding was not specified and the study was short and small. FDA also listed a related 2021 report on clock-gene expression in night-shift workers. FDA found no study in people with insomnia and no clinical safety study. Animal: monkey hormone studies and mouse lifespan and tumour studies, all with a fixed regimen and (in mice) females only. Cell: telomerase and telomere-length work in human fibroblast cultures. In-vitro rat pineal tissue showed no direct melatonin effect. No phase 2 or 3 trial exists.

Last verified 2026-09-29 · how we verify

3. D · AspartateD4. G · GlycineG2. E · GlutamateE1. A · AlanineANC

Schematic

  • Water-avoiding
  • Negative charge
  • Glycine or proline

Schematic from the amino-acid sequence — not an experimental structure

4 amino acids, one bead each, coloured by type, N-terminus to C-terminus. The chain shape is illustrative; it is not the real 3D shape of Epitalon.

Acts on
No confirmed molecular target (laboratory studies report effects on telomerase expression, melatonin and circadian-clock gene expression, and gene regulation)
Taken as
No approved route. In the few human studies it was given as a sublingual spray (women working night shifts) and as an injection beside the eye (retinitis pigmentosa, parabulbar). Animal studies used subcutaneous injection in mice and intramuscular injection in monkeys. The products FDA reviewed in 2026 were nominated for subcutaneous injection, but no human study of that route was found. Human absorption and bioavailability are unknown.
Approval status
Not approved by FDA or any other regulator we found, and not a component of any FDA-approved drug. There is no USP or NF monograph. FDA's 2026 briefing describes the substances as not well characterised and states no FDA-approved product contains epitalon.[src]
Molecular formula and weight
Free base C14H22N4O9, 390.35 g/mol (sequence Ala-Glu-Asp-Gly); acetate salt 450.40 g/mol. FDA treats the two as different bulk substances.[src]
Orphan designation
Received an FDA orphan drug designation for retinitis pigmentosa on 2 September 2010; it was withdrawn or revoked on 6 January 2016.[src]
FDA advisory committee vote
On 24 July 2026 the Pharmacy Compounding Advisory Committee voted 7 to 4, with 1 abstention, in favour of adding epitalon to the 503A bulks list, against the recommendation of FDA staff. The vote is advisory; notice-and-comment rulemaking would still be needed.[src]

Inside the body

What Epitalon does, step by step

Watch the 3D journey →
  1. 01Brain

    Copied from a pineal gland extract

    Epitalon was designed by looking at which amino acids are in epithalamin, an extract made from cow pineal glands. The pineal gland is a small gland deep in the brain that makes the sleep hormone melatonin. Epitalon is a four-piece copy made in a lab.

    For experts

    Epithalamin is a polypeptide complex extracted from bovine pineal gland; epitalon (Ala-Glu-Asp-Gly) is a tetrapeptide synthesised on the basis of the amino-acid content of that extract and is described as a synthetic analogue with similar biological effects. FDA considers the two different substances. A 2025 review reports that in 2017 the tetrapeptide was detected by LC-MS in a pineal gland polypeptide complex solution. The idea that it acts as a pineal regulator rests largely on work from the originating group.[src][src]

  2. 02Bloodstream

    What happens after it enters the blood is unknown

    Nobody has measured how fast the body breaks epitalon down or where it goes. Very short peptides like this are often broken up quickly, but that has not been shown for epitalon.

    For experts

    FDA found no pharmacokinetic data for epitalon free base or acetate in humans, and no acute-toxicity or repeat-dose toxicity studies. The only distribution data are a single report in pregnant rabbits given one dose of fluorescent-labelled epitalon, in which fluorescence was seen one hour later in maternal and fetal liver, lungs, stomach and intestines, but the study did not show the signal came specifically from labelled epitalon. A 2025 review states that information on the peptide's safety is missing from the published work and notes, as a general point, that short peptides such as epitalon are typically unstable and degrade rapidly in vivo.[src][src]

  3. 03Brain

    Melatonin and stress hormone in old monkeys

    In old female monkeys, ten days of epitalon raised evening melatonin and made their daily cortisol (stress hormone) rhythm look more normal. In young monkeys, melatonin did not change, but cortisol went down in both morning and evening. A separate test on rat pineal glands in a dish found no direct effect on melatonin.

    For experts

    In female rhesus monkeys given epitalon by intramuscular injection for 10 days, evening serum melatonin rose more than 4-fold and evening cortisol fell by about 30% in the old animals; in young animals melatonin did not change significantly, while cortisol fell in both morning and evening samples (Goncharova 2001, as summarised by FDA). FDA noted that the functional relevance for sleep was unclear and that no sleep-behaviour or EEG studies were found. In rat pineal glands perifused in vitro, epitalon did not change basal or isoproterenol-stimulated melatonin release in young or old animals (Djeridane 2003), so a direct action on the pineal is not supported and the mechanism in vivo is unknown.[src][src][src]

  4. 04Brain

    A small human study on a melatonin marker

    One small study gave women who work night shifts either epitalon or a dummy spray under the tongue. In women who started with low levels of a melatonin by-product in urine, the level went up in the epitalon group. The study did not show that anyone slept better.

    For experts

    Ivko 2021 was described by FDA as a randomised placebo-controlled study in healthy women aged 40-50 (n = 75) mainly working night shifts. Of 40 women with low urinary 6-sulfatoxymelatonin, those given sublingual AEDG for 20 days had a 1.7-fold rise, which the authors described as restoring age-appropriate values, while placebo showed no change. The authors also reported changes in clock-gene expression in blood cells and better psycho-emotional condition in 83% versus 25% on placebo, but did not say how this was measured. FDA noted blinding was not specified, duration was short, the sample was small, and no sleep outcomes were assessed. It has not been shown to treat insomnia.[src][src]

  5. 05Elsewhere

    Telomerase switched on in cultured cells

    Telomeres are protective caps at the ends of our DNA that get shorter as cells divide. A 2003 lab report said epitalon made human cells in a dish switch on the enzyme that rebuilds these caps. This was done in cell cultures only, and it has not been shown to happen in a living person.

    For experts

    Khavinson et al. (2003) reported that adding epitalon to telomerase-negative human fetal fibroblast cultures induced expression of the catalytic subunit (hTERT), telomerase activity and telomere elongation. FDA describes these as cell-culture findings, and the reports it cites come from the originating group. No study has shown telomere lengthening in living humans. FDA also notes the other side of this mechanism: longer telomeres are generally associated with higher cancer risk, so continuous telomerase activation is a theoretical carcinogenicity concern.[src][src]

  6. 06Elsewhere

    Mouse studies of lifespan and tumours (animal only)

    In female mice given epitalon on a repeating schedule for life, average lifespan did not change, but the longest-lived mice lived a little longer and fewer developed one kind of blood cancer. Other mouse studies reported fewer breast tumours. These are mouse results only.

    For experts

    In female Swiss-derived SHR mice (54 per group) treated subcutaneously on 5 consecutive days each month from 3 months of age until natural death, epitalon did not change mean lifespan, food intake or body weight, but increased maximum lifespan by 12.3% and lifespan of the last 10% of survivors by 13.3%, reduced chromosome aberrations in bone marrow by 17.1%, left total spontaneous tumour incidence unchanged and reduced leukaemia 6.0-fold (Anisimov 2003). In HER-2/neu transgenic mice, epitalon reduced the number and size of mammary tumours and lowered HER-2/neu mRNA 3.7-fold in tumours (Anisimov 2002). FDA judged these studies too limited for safety conclusions: fixed regimen with no dose-response, females only, exposure of at most about 5.5 months, and chromosome-aberration comparisons that relied on an unvalidated historical control group of four mice.[src][src][src]

For experts

The detail

Epitalon (epithalon, AEDG) is a synthetic linear tetrapeptide, L-Ala-L-Glu-L-Asp-Gly (C14H22N4O9, 390.35 g/mol), designed by V. Khavinson's group at the St Petersburg Institute of Bioregulation and Gerontology from the amino-acid composition of epithalamin, a polypeptide extract of bovine pineal gland; FDA treats epitalon and epithalamin as different substances. It is unmodified: no D-amino acids, lipidation or other half-life engineering. Epitalon is a common name, not a USAN, and the free base (CAS 307297-39-8) and the acetate salt (CAS 307297-40-1) are distinct bulk substances. Reported effects, mostly from the originating group, include induction of telomerase catalytic-subunit expression and telomere elongation in cultured human fetal fibroblasts, increased evening melatonin and normalised cortisol rhythm in old rhesus monkeys, fewer or smaller spontaneous tumours of some types in some mouse models, and altered gene expression in several tissues. An in-vitro rat pineal perifusion study found no direct effect on melatonin release, and the mechanism in vivo is unknown. Human evidence is limited to three small reports identified by FDA: a report of benefit in retinitis pigmentosa after injection beside the eye, and two 2021 reports of sublingual use in women working night shifts, one of them a small randomised placebo-controlled study that measured a urinary melatonin metabolite and clock-gene expression. No pharmacokinetic data exist in humans or, apart from one unvalidated fluorescence-tracer report in rabbits, in animals. No approved product contains epitalon and there is no USP or NF monograph. An orphan designation for retinitis pigmentosa (FDA, 2010) was withdrawn in 2016. FDA staff recommended in 2026 against adding it to the 503A bulks list, citing weak characterisation, no effectiveness data for insomnia and no human safety data, and flagging a theoretical carcinogenicity concern from telomerase activation; the advisory committee voted 7 to 4 (1 abstention) in favour on 24 July 2026, which is advisory only.

Evidence: The evidence is small, mostly from a single research network, and largely not from modern controlled trials. Human: (1) a 2002 report from the originating group that injection beside the eye produced a positive clinical effect in 90% of cases in patients with degenerative retinal lesions (the abstract gives no patient numbers or comparison; a 2025 review's account describes 162 patients and a comparison group on conventional treatment, but no placebo and no between-group results); (2) a small randomised placebo-controlled sublingual study in women aged 40-50 working night shifts (Ivko 2021, 75 women, 40 with low urinary melatonin metabolite split into treatment and placebo groups for 20 days) in which the treated group's metabolite level rose 1.7-fold; sleep outcomes were not assessed and no safety data were reported; FDA noted blinding was not specified and the study was short and small. FDA also listed a related 2021 report on clock-gene expression in night-shift workers. FDA found no study in people with insomnia and no clinical safety study. Animal: monkey hormone studies and mouse lifespan and tumour studies, all with a fixed regimen and (in mice) females only. Cell: telomerase and telomere-length work in human fibroblast cultures. In-vitro rat pineal tissue showed no direct melatonin effect. No phase 2 or 3 trial exists.[src][src][src][src][src][src][src]

Known safety signals

  • No clinical safety studies were found. FDA reported that the nominations included none and that its literature search found none; no pharmacokinetic, acute-toxicity, repeat-dose toxicity or developmental and reproductive toxicity studies were identified either.[src]
  • Theoretical cancer concern: because epitalon is reported to activate telomerase and lengthen telomeres, and longer telomeres are generally associated with higher cancer risk, FDA said continuous exposure could in principle let cells avoid ageing and become cancerous. The mouse studies were too short and too limited to rule this out.[src]
  • Injected peptides can trigger immune responses and can clump together (aggregate). FDA said information on aggregation was lacking, so it could not rule out immune reactions, especially with injection. It also listed peptide-related impurities and inconsistent naming (different salts and derivatives sold under the same name) as quality and safety risks.[src]
  • FDA searched its adverse-event reporting system through 8 December 2025 and found no reports for epitalon. FDA cautioned that this cannot show safety because reporting is voluntary and compounders generally do not report events.[src]
  • Health Canada listed epitalon among unauthorized injectable peptides it has seized, and warned that unauthorized peptide products carry general risks including infection, allergic reaction, contamination and interactions; it stated that a research-use-only label does not make a product legal. These warnings cover the category, not epitalon specifically.[src]
  • The authors of a 2025 review said that before epitalon could be approved as a drug substance, more studies are needed on short- and long-term toxicity, genotoxicity, carcinogenic potential and interactions.[src]

Around the world

Is Epitalon legal where you live?

CountryStatusWhat it meansVerified
AustraliaNot approvedNo epitalon product is on the ARTG. It counts as an unapproved peptide, and advertising or supplying it is likely unlawful.Details →source2026-09-29
BrazilNot approvedNo Brazilian registration for epitalon; the unregistered-peptide rules applyDetails →source2026-09-29
CanadaProhibitedNot authorised; named in Health Canada's seizure notices from 2025 and 2026Details →source2026-09-29
ChinaNot approvedNo NMPA approval found for epitalon; it cannot lawfully be sold as a medicine in China.Details →source2026-09-29
European UnionNot approvedNo EU marketing authorisation; not listed in EMA or Union Register dataDetails →source2026-09-29
IndiaNot approvedNot approved in India: no CDSCO marketing permission found for Epitalon; making or selling it as a medicine would be unapprovedDetails →source2026-09-29
JapanNot approvedNot an approved medicine in Japan; epitalon is absent from PMDA's approved-drug lists and package-insert databaseDetails →source2026-09-29
MexicoNot approvedNot approved in Mexico; unregistered peptide named in a July 2026 billDetails →source2026-09-29
New ZealandNot approvedNo Medsafe-approved medicine contains epitalon; pineal peptides are prescription-onlyDetails →source2026-09-29
United Arab EmiratesNot approvedNot approved in the UAE: no marketing authorisation for epitalon; unapproved peptide products are under EDE enforcementDetails →source2026-09-29
United KingdomNot approvedEpitalon is not licensed in the UKDetails →source2026-09-29
United StatesNot approvedNo FDA approval; an advisory panel voted in July 2026 to recommend considering it, but the vote is not bindingDetails →source2026-09-29

Recent history

  1. 2026-07-23

    FDA advisory committee votes on seven peptides for the 503A compounding list, against FDA staff advice

  2. 2026-04-15

    FDA removes 12 peptides from the 'Category 2' safety-risk list

Full timeline →

Related molecules

Sources (51)

  1. 01FDA Briefing Document, Pharmacy Compounding Advisory Committee, July 23-24, 2026: Evaluation of Epitalon-Related Bulk Drug Substances (Epitalon (Free Base) and Epitalon Acetate) for the 503A Bulk Drug Substances ListU.S. Food and Drug Administration · 2026-07 · accessed 2026-09-29
  2. 02Overview of Epitalon: Highly Bioactive Pineal Tetrapeptide with Promising PropertiesInternational Journal of Molecular Sciences (via PubMed Central) · 2025-03-17 · accessed 2026-09-29
  3. 03Pineal-regulating tetrapeptide epitalon improves eye retina condition in retinitis pigmentosaNeuroendocrinology Letters (via PubMed) · 2002-08 · accessed 2026-09-29
  4. 04Effect of Epitalon on biomarkers of aging, life span and spontaneous tumor incidence in female Swiss-derived SHR miceBiogerontology (via PubMed) · 2003 · accessed 2026-09-29
  5. 05Epithalon peptide induces telomerase activity and telomere elongation in human somatic cellsBulletin of Experimental Biology and Medicine (via PubMed) · 2003-06 · accessed 2026-09-29
  6. 06Regulatory effect of Epithalon on production of melatonin and cortisol in old monkeysBulletin of Experimental Biology and Medicine (via PubMed) · 2001-04 · accessed 2026-09-29
  7. 07Effect of a synthetic pineal tetrapeptide (Ala-Glu-Asp-Gly) on melatonin secretion by the pineal gland of young and old ratsJournal of Endocrinological Investigation (via PubMed) · 2003-03 · accessed 2026-09-29
  8. 08Inhibitory effect of the peptide epitalon on the development of spontaneous mammary tumors in HER-2/neu transgenic miceInternational Journal of Cancer (via PubMed) · 2002-09-01 · accessed 2026-09-29
  9. 09Bulk-List Bound? PCAC Backs Majority of Peptides in Two-Day Public MeetingMcDermott Will & Schulte · 2026-07-27 · accessed 2026-09-29
  10. 10Think twice before injecting peptides bought online: unauthorized products can seriously harmHealth Canada · 2026-04-09 · accessed 2026-09-29
  11. 11ARTG keyword search for 'epitalon' (no matching results)Therapeutic Goods Administration (TGA) · 2026-09-29 · accessed 2026-09-29
  12. 12Understanding your responsibilities when importing, compounding and supplying unapproved peptide productsTherapeutic Goods Administration (TGA) · 2026-04-13 · accessed 2026-09-29
  13. 13TGA strengthens compliance focus on unapproved peptide products as part of evolving risk responseTherapeutic Goods Administration (TGA) · 2026-06-10 · accessed 2026-09-29
  14. 14Dados abertos: registro de medicamentos (DADOS_ABERTOS_MEDICAMENTOS.csv)Agência Nacional de Vigilância Sanitária (Anvisa) · 2026-09-29 · accessed 2026-09-29
  15. 15Checamos: peptídeos que prometem milagres NÃO estão registrados na AnvisaAgência Nacional de Vigilância Sanitária (Anvisa) · 2026-07-02 · accessed 2026-09-29
  16. 16Unauthorized injectable peptide drugs seized from Optimum Wellness Centre in Calgary, Alberta may pose serious health risksHealth Canada · 2025-04-02 · accessed 2026-09-29
  17. 17Drug Product Database API: active-ingredient search for epitalonHealth Canada (Drug Product Database) · 2026-09-29 · accessed 2026-09-29
  18. 18Drug Administration Law of the PRC (中华人民共和国药品管理法)National Medical Products Administration (NMPA) · 2019-08-26 · accessed 2026-09-29
  19. 19Provisions for Drug Registration (SAMR Order No. 27; 药品注册管理办法)State Administration for Market Regulation (SAMR) · 2020-01-22 · accessed 2026-09-29
  20. 20CDE public register of accepted drug applications (受理品种目录浏览)Center for Drug Evaluation (CDE), NMPA · 2026-09-29 · accessed 2026-09-29
  21. 21EMA medicines data (JSON report): human and veterinary medicines, with authorisation statusEuropean Medicines Agency · 2026-09-29 · accessed 2026-09-29
  22. 22Union Register of medicinal products for human useEuropean Commission · 2026-09-29 · accessed 2026-09-29
  23. 23Directive 2001/83/EC on the Community code relating to medicinal products for human use (consolidated text, 1 January 2025)European Union (EUR-Lex) · 2025-01-01 · accessed 2026-09-29
  24. 24Manufacturing and marketing of unapproved drug products containing Enclomiphene and its combinations (sets out the New Drugs rule for unapproved products)Central Drugs Standard Control Organisation (CDSCO) · 2026-08-10 · accessed 2026-09-29
  25. 25CDSCO Subject Expert Committee (SEC) recommendations index (records reviewed 2015 to September 2026)Central Drugs Standard Control Organisation (CDSCO) · 2026-09-23 · accessed 2026-09-29
  26. 26Public Notice dated 18 May 2026: injectable preparations do not fall under the definition of cosmeticsCentral Drugs Standard Control Organisation (CDSCO) · 2026-05-18 · accessed 2026-09-29
  27. 27Approved new drugs list (Japanese), fiscal 2026 to date, covering approvals from May to September 2026 (承認品目一覧(新医薬品))Pharmaceuticals and Medical Devices Agency (PMDA) · 2026-09 · accessed 2026-09-29
  28. 28List of Approved Drugs, April 2004 to February 2026 (new drugs)Pharmaceuticals and Medical Devices Agency (PMDA) · 2026 · accessed 2026-09-29
  29. 29Prescription drug package insert and review report search (医療用医薬品 添付文書等情報検索)Pharmaceuticals and Medical Devices Agency (PMDA) · 2026-09-29 · accessed 2026-09-29
  30. 30Act on Securing Quality, Efficacy and Safety of Products Including Pharmaceuticals and Medical Devices (PMD Act), consolidated textDigital Agency (e-Gov Law Search) · 2026-05-21 · accessed 2026-09-29
  31. 31Personal import of pharmaceuticals and related products (医薬品等の個人輸入について)Ministry of Health, Labour and Welfare (MHLW) · 2025 · accessed 2026-09-29
  32. 32Registros sanitarios de medicamentos alopáticos expedidos 2026COFEPRIS (Comisión Federal para la Protección contra Riesgos Sanitarios) · 2026-08-04 · accessed 2026-09-29
  33. 33Iniciativa con proyecto de decreto por el que se adiciona un artículo 215 Bis a la Ley General de Salud, en materia de regulación de péptidos de investigación de uso estético y deportivoCámara de Diputados, Sistema de Información Legislativa (dip. Ivonne Ortega Pacheco, MC) · 2026-07 · accessed 2026-09-29
  34. 34Listados de registros sanitarios de medicamentos (visor y listas anuales)COFEPRIS (Comisión Federal para la Protección contra Riesgos Sanitarios) · 2025-08-21 · accessed 2026-09-29
  35. 35Alerta sanitaria: comercialización ilegal de productos con tirzepatida sin registro sanitarioCOFEPRIS (Comisión Federal para la Protección contra Riesgos Sanitarios) · 2026-02-09 · accessed 2026-09-29
  36. 36Data sheets index (medicines with consent to be distributed in New Zealand)Medsafe (New Zealand Medicines and Medical Devices Safety Authority) · 2026-09-29 · accessed 2026-09-29
  37. 37Medicines Classification Database (Schedule 1, Medicines Regulations 1984)Medsafe (New Zealand Medicines and Medical Devices Safety Authority) · 2026-09-25 · accessed 2026-09-29
  38. 38Consumer advisory: Unapproved peptide products health warningMedsafe (New Zealand Medicines and Medical Devices Safety Authority) · 2026-05-21 · accessed 2026-09-29
  39. 39Medicines Act 1981 (version as at 10 July 2026)New Zealand Parliamentary Counsel Office · 2026-07-10 · accessed 2026-09-29
  40. 40UAE cracks down on illegal weight-loss products, targets 71 violatorsKhaleej Times · 2026-07-25 · accessed 2026-09-29
  41. 41UAE weight-loss drug crackdown: 71 sources, 14 influencers face actionGulf News · 2026-07-25 · accessed 2026-09-29
  42. 42Pharmaceutical licensing and drug registration in the UAE (Federal Decree-Law 38 of 2024)Kayrouz and Associates · 2026-03-18 · accessed 2026-09-29
  43. 43Abu Dhabi health authority launches online form for reporting side effects from peptide productsEmirates 24|7 · 2026-09-25 · accessed 2026-09-29
  44. 44Federal Decree-Law No. (38) of 2024 on Medical Products, the Pharmacy Profession and Pharmaceutical Establishments (Arabic text)Emirates Drug Establishment (EDE) · 2024-10-01 · accessed 2026-09-29
  45. 45Find product information about medicines (MHRA Products register)Medicines and Healthcare products Regulatory Agency (MHRA) · 2026-09-25 · accessed 2026-09-29
  46. 46The Human Medicines Regulations 2012, regulation 46 (prohibition on sale or supply of unauthorised medicinal products)UK Government (legislation.gov.uk) · 2012 · accessed 2026-09-29
  47. 47Borderline products: how to tell if your product is a medicineMedicines and Healthcare products Regulatory Agency (MHRA) · 2026-07-02 · accessed 2026-09-29
  48. 48Two arrested during the MHRA's largest ever seizure of unlicensed weight loss medicinesMedicines and Healthcare products Regulatory Agency (MHRA) · 2026-05-29 · accessed 2026-09-29
  49. 49MHRA disrupts second manufacturing facility suspected to be involved in the manufacture of illegal weight loss medicinesMedicines and Healthcare products Regulatory Agency (MHRA) · 2026-02-25 · accessed 2026-09-29
  50. 50Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (Category 2 and withdrawn nominations)U.S. Food and Drug Administration · 2026-04-22 · accessed 2026-09-29
  51. 51July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory CommitteeU.S. Food and Drug Administration · 2026-08-06 · accessed 2026-09-29